Evaluation of the efficacy of ombitasvir and paritaprevir with ritonavir for Japanese hepatitis C patients: a prospective study in real-life settings.

Evaluation of the efficacy of ombitasvir and paritaprevir with ritonavir for Japanese hepatitis C patients: a prospective study in real-life settings. - The efficacy of ombitasvir and paritaprevir with ritonavir for Japanese hepatitis C patients

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000021276

Enrollment

100

Registered

2016-03-10

Start date

2015-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic hepatitis C

Interventions

combination tablet of ombitasvir/paritaprevir/r (12.5 mg/75 mg/50 mg) two tablets once daily for 12 weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: chronic hepatitis C and compensated cirrhotic patients with HCV genotype 1b

Exclusion criteria

Exclusion criteria: decompensated cirrhosis

Design outcomes

Primary

Measure	Time frame
sustained virological response (SVR) at 12 week and 24 week after the end of treatment	—

Secondary

Measure	Time frame
incidence rate of adverse events	—

Countries

Japan

Contacts

Public ContactHitomi Sezaki

Toranomon Hospital hepatology

hitomis@mx1.harmonix.ne.jp03-3588-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026